ReviewBiochemical Society transactions2026
A pore is a pore is a pore (or a hub?): VDAC oligomerization in mitochondrial connectivity and modulation.
Review in Biochemical Society transactions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mitochondrial Voltage-Dependent Anion Channel: From a Passive Pore to a Cellular Hub Through Protein Complexation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
For decades, the voltage-dependent anion-selective channel (VDAC), formerly known as the mitochondrial porin, was considered a simple pore enabling nearly free permeability across the outer mitochondrial membrane. This simplified view has been progressively dismantled through the discovery of three mammalian isoforms (VDAC1, VDAC2, and VDAC3) with the gradual attribution, often serendipitous, of diverse cellular roles beyond passive metabolite exchange. Recent advances in cryo-electron microscopy have catalyzed a breakthrough in VDAC research. Three converging lines of evidence are reshaping our understanding: (a) high-resolution structures of VDAC within its native protein complexes; (b) discovery of unexpected functions, including phospholipid scrambling and regulation of outer membrane permeabilization through higher-order oligomeric assemblies; and (c) structural determination of VDAC interactions with macromolecules, as well as small-molecule modulators. Collectively, these insights have strengthened the consideration of VDAC as a multifunctional signaling hub and therapeutic target, with emerging small molecules and peptides designed to modulate gating, oligomerization, and interfering with interacting partners. The aim of this review is to summarize current structural, functional, and pharmacological advances in VDAC biology, emphasizing how oligomerization dynamics and isoform specificity orchestrate mitochondrial behavior and offering perspectives on therapeutic strategies for diseases driven by mitochondrial dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.